2
项与 TIL 1383I TCR transduced T cells(NCI) 相关的临床试验Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes: A Phase 1b Study
Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced melanoma.
Transfer of Genetically Engineered Lymphocytes in Melanoma Patients: A Phase 1 Dose Escalation Study
This is a phase one trial to determine if genetically engineered lymphocytes can be safely delivered to patients with metastatic melanoma.
100 项与 TIL 1383I TCR transduced T cells(NCI) 相关的临床结果
100 项与 TIL 1383I TCR transduced T cells(NCI) 相关的转化医学
100 项与 TIL 1383I TCR transduced T cells(NCI) 相关的专利(医药)
100 项与 TIL 1383I TCR transduced T cells(NCI) 相关的药物交易